Intervention: Buprenorphine
Trial phase: Phase 4
ATC code: N02AE01 | N07BC01 | N07BC51
SMILES: COC12CCC3(CC1C(C)(O)C(C)(C)C)C1Cc4ccc(O)c5c4C3(CCN1CC1CC1)C2O5
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 241
Group description: Trade name is Norspan. Buprenorphine 5μg/h, 10 μg/h, 20 μg/h patches will be used (4 patches a box). Patch will be administered every 7th day.

Buprenorphine: 8weeks treatment with Norspan®(Buprenorphine)
Eligibility criteria:
Inclusion Criteria:

20 years old or above male or female Korean patients
Patients who have spinal disorders related pain
Patients who had been treated with weak opioids and/or NSAIDs before study participation
Patients who have moderate to severe pain intensity
Naïve patients for Buprenorphine (Naïve patient are defined as those who had not been treated with Buprenorphine for 90 days)
Patients who signed a written informed consent form

Exclusion Criteria:

Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant. UNLESS they are:

women whose partners have been sterilized by vasectomy or other means
using two birth control methods. The two methods can be a double barrier method or a barrier method plus a hormonal method. Adequate barrier methods of contraception include: diaphragm, condom (by the partner), intrauterine device (copper or hormonal), sponge or spermicide. Hormonal contraceptives include any marketed contraceptive agent that includes an estrogen and/or a progestational agent.
Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive urine pregnancy test
Patients with known hypersensitivity to buprenorphine or to any of the excipients
Patients with severely impaired respiratory function or respiratory depression status
Patients concurrently receiving MAOIs or who have received MAOIs within the previous two weeks
Patients with convulsive disorders, head injury, shock, a reduced level of consciousness of uncertain origin, intracranial lesions or increased intracranial pressure, or in patients with severe hepatic impairment
Patients with biliary tract disorders
Patients known to have, or suspected of having a history of drug abuse
Patients with history of opioid or drug dependence
Patients who are concurrently taking other CNS depressants or muscle relaxants that may cause respiratory depression, hypotension, profound sedation or potentially result in coma.
Patients who are taking Buprenorphine or strong opioid.
Any situation where Buprenorphine is contraindicated
Major surgery within 1 month prior to screening or planned surgery Mainly pain originated other than spinal disorders disease
Non-malignant patients or cancer patients who are receiving any oncology treatment that could affect the measure of pain control
With a disability that may prevent the patient from completing all study requirements and in particular, interfere with 24hrs pain intensity score
Clinically significant impairment of cardiovascular, respiratory and renal function
Patient who needs acute dose titration or whose pain intensity fluctuate significantly in a short period according to investigator's judgment
Having used other investigational drugs at the time of enrollment, or within 30 days of enrollment